Allstate Corp Has $1.27 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Allstate Corp lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 99.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,126 shares of the medical equipment provider’s stock after buying an additional 7,052 shares during the quarter. Allstate Corp’s holdings in Zimmer Biomet were worth $1,270,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZBH. M&T Bank Corp increased its position in shares of Zimmer Biomet by 15,705.6% in the fourth quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock worth $321,158,000 after purchasing an additional 3,548,998 shares during the period. Dodge & Cox grew its position in Zimmer Biomet by 5.1% in the third quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after acquiring an additional 1,118,710 shares during the last quarter. AQR Capital Management LLC grew its position in Zimmer Biomet by 276.6% in the second quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after acquiring an additional 955,284 shares during the last quarter. Capital International Investors grew its position in Zimmer Biomet by 11.5% in the third quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after acquiring an additional 778,467 shares during the last quarter. Finally, Pacer Advisors Inc. grew its holdings in shares of Zimmer Biomet by 4,020.2% during the fourth quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock worth $62,742,000 after purchasing an additional 680,818 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ZBH shares. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wells Fargo & Company cut their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. BTIG Research reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd. Canaccord Genuity Group set a $83.00 price target on Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Robert W. Baird set a $92.00 target price on Zimmer Biomet in a research report on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $82.46 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The stock has a market cap of $15.95 billion, a P/E ratio of 21.42, a PEG ratio of 1.92 and a beta of 0.48. The business’s 50-day moving average price is $87.96 and its two-hundred day moving average price is $90.63. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same period last year, the company earned $1.81 EPS. The business’s quarterly revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.2%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by insiders.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.